Clinical Trials in Phoenix

Showing 4901-4920 of 12,606 trials

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

NCT01605084

The purpose of this study is to determine the proportion of subjects with HIV-1 RNA \< 50 c/mL at Week 48 in patients who failed their first line therapy containing a non-nucleoside reverse transcriptase inhibitor (NNRTI) or an integrase inhibitor

HIV

Bristol-Myers SquibbStarted Jun 2012

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Little Rock, Arkansas, United States +11 more locations

COMPLETEDPhase 2< 1 mile

A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury

NCT05309200

OCE-205 is being tested to treat participants who have developed Hepatorenal Syndrome-Acute Kidney Injury as a complication of cirrhosis with ascites. The study aims are to evaluate the safety and efficacy of OCE-205 at various doses. Participants will receive treatment by intravenous infusion. Participants will continue with this treatment until participants meets primary endpoint or any discontinuation criteria.

CirrhosisAscitesHepatorenal Syndrome+1 more

Ocelot Bio, Inc47 participantsStarted Apr 2022

Phoenix, Arizona, United States • Los Angeles, California, United States • San Francisco, California, United States +20 more locations

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury

Find Trials by Condition in Phoenix

All Inclusive Kodex - EPD Study

Approaches and Decisions for Acute Pediatric TBI Trial

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants

Micronized dHACM vs. Saline in the Treatment of Osteoarthritis of the Knee

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)

The Canadian/US Integrative Oncology Study

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Survival Prolongation by Rationale Innovative Genomics

OCS Liver PROTECT Continued Access Protocol (CAP) Continuation Post-Approval Study

Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients

A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention

Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer

A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

iCanCope With Sickle Cell Pain